Media Articles Related to Probenecid and Colchicine (Probenecid / Colchicine)
Gout Attacks More Common at Night: Study
Source: MedicineNet Arthritis Specialty [2014.12.12]
Title: Gout Attacks More Common at Night: Study
Category: Health News
Created: 12/11/2014 12:00:00 AM
Last Editorial Review: 12/12/2014 12:00:00 AM
Nighttime gout attack risk more than two times higher than in the daytime
Source: Arthritis / Rheumatology News From Medical News Today [2014.12.11]
Novel research reveals that the risk of acute gout attacks is more than two times higher during the night or early morning hours than it is in the daytime.
Nighttime Risky for Gout
Source: MedPage Today Rheumatology [2014.12.11]
(MedPage Today) -- When the sun goes down, gout attacks.
Gout: data from Phase III studies of lesinurad in combination with allopurinol
Source: Gout News From Medical News Today [2014.11.19]
AstraZeneca has presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination...
Source: MedicineNet Amyloidosis Specialty [2014.10.14]
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 10/14/2014 12:00:00 AM
Clinical Trials Related to Probenecid and Colchicine (Probenecid / Colchicine)
Safety and Tolerance of Zidovudine With Probenecid and the Effect of Probenecid on Zidovudine Pharmacokinetics Over Four Weeks [Completed]
To evaluate the interaction of probenecid with zidovudine (AZT). Because AZT is eliminated
quickly from the body, it must be taken frequently. A previous study showed that probenecid
slowed the elimination of AZT without side effects, but that study lasted only 5 days. This
study is to see whether this effect continues for 1 month and whether the continuation of
probenecid and AZT is free of side effects over 1 month.
Influence of Probenecid and Quinine on the Pharmacokinetics of Azidothymidine [Completed]
Part I studies the effect of quinine on how zidovudine (AZT) is used by the body and
eliminated through the kidneys in HIV infected patients. Part II studies the effect of
probenecid and quinine on the same aspects.
Because AZT leaves the bloodstream quickly, patients must take the drug frequently to keep
adequate amounts in their bodies. Probenecid and quinine may slow down the rate at which AZT
leaves the body. Therefore, taking these drugs along with AZT may reduce the amount of AZT
needed for treatment.
10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors [Completed]
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Probenecid may increase the effectiveness of
10-propargyl-10-deazaaminopterin by making tumor cells more sensitive to the drug.
PURPOSE: Phase I trial to study the effectiveness of combining
10-propargyl-10-deazaaminopterin and probenecid in treating patients who have advanced solid
Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy [Recruiting]
The study is being done to understand why some patients with epilepsy (disease of recurrence
of seizures) do not respond very well to drug treatment with anticonvulsants.
Despite the availability of many anticonvulsants, about 30% of patients with epilepsy are
resistant to them. The cause of the resistance is not clear, but one of the reasons could be
an increased amount of proteins in the cells of the body called transporter proteins.
Transporter proteins are a group of proteins that help to defend the body against toxins,
including drugs, by pumping them out of the cells. Studies have shown that the number of
transporter proteins is higher in the parts of the brain that trigger seizures when compared
to other parts of the brain.
Studies in animals have shown that taking an anticonvulsant with an inhibitor (meaning "to
stop" or "to reduce") of a transporter protein can increase the concentration of that
anticonvulsant inside the brain cells. The main purpose of the study is to determine if
taking an anticonvulsant and a transporter protein inhibitor will change the brain
concentration of the anticonvulsant.
In this study, a single dose of phenytoin (Dilantin® is a brand name anticonvulsant which
has phenytoin as its active ingredient), a commonly used anticonvulsant, will be given once
by itself, and then will be given a separate time with a single (i. e. one time only) dose of
probenecid. Probenecid, a medicine used commonly to treat gout (a disease of increased uric
acid), is known to be an inhibitor of transporter proteins. The study will use
electroencephalogram or EEG (recording of brain wave activities) to determine if the EEG
pattern when probenecid is given, will be different from the EEG pattern when phenytoin is
given alone. This will suggest that probenecid has affected the brain concentration of
Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies. [Completed]
Objective 1: Determine the safety and toxicity profile of Tamiflu administered in
combination with probenecid in healthy adults. Objective 2: Determine the pharmacokinetic
profile of Tamiflu and probenecid in healthy adults.